TradeFlare's AI research teams analysed GRAL on 9 market nights between September 16, 2026 and October 6, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| October 6, 2026 | HOLD | $154.08 | — / — | +2.2% | not yet | The current market regime and stock-specific flags suggest a cautious approach, making a short-term outlook appropriate. |
| October 2, 2026 | HOLD | $132.56 | $152.49 / $112.68 | -1.9% | not yet | The PEAD signal suggests short-term momentum, but fundamental and risk factors warrant a cautious approach. |
| October 1, 2026 | HOLD | $140.12 | $168.14 / $119.10 | +0.0% | not yet | The stock has experienced a significant run-up, and while technically bullish, fundamental concerns and high risk warrant a cautious approach. |
| September 30, 2026 | HOLD | $136.57 | — / — | -5.2% | not yet | The current market regime and stock-specific flags suggest a cautious approach, favoring short-term trading if a clear opportunity arises. |
| September 29, 2026 | HOLD | $132.63 | — / — | +0.5% | not yet | The stock is currently in a volatile state post-earnings, making short-term entry risky. |
| September 28, 2026 | HOLD | $126.89 | — / — | +16.2% | not yet | The stock has experienced a significant run-up and exhibits high volatility, making short-term trading decisions crucial. |
| September 25, 2026 | HOLD | $125.21 | — / — | +12.9% | not yet | The stock has experienced a significant run-up and is showing signs of extended price action, making it unsuitable for a new entry at this time. |
| September 17, 2026 | HOLD | $75.11 | — / — | +56.6% | not yet | RSI Pullback (RSI5=24.5) indicates oversold conditions and potential for a short-term mean-reversion bounce. |
| September 16, 2026 | HOLD | $75.89 | — / — | +44.5% | not yet | Galleri test volume growth and an upcoming FDA review for its cancer detection product. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.